CD47 and diffuse large B-cell lymphoma: Furthermore, in DLBCL patients treated with standard therapy (rituximab–CHOP; cyclophosphamide, doxorubicin, vincristine, and prednisone), the high mRNA expression of CD47 associated with poor surival in the aggressive non Germinal Center B cell subtype (non-GCB) [188].